Stay updated with breaking news from Zymeworks Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Zymeworks Inc. (NYSE:ZYME – Get Rating) major shareholder Ecor1 Capital, Llc bought 3,350,000 shares of the stock in a transaction dated Friday, June 16th. The stock was bought at an average price of $8.12 per share, with a total value of $27,202,000.00. Following the purchase, the insider now owns 13,437,473 shares of the company’s stock, […]
Shares of Zymeworks Inc. (NYSE:ZYME – Get Rating) have been assigned an average recommendation of “Moderate Buy” from the nine ratings firms that are currently covering the company, MarketBeat.com reports. Four investment analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month target […]
EcoR1 Capital LLC bought a new stake in Zymeworks Inc. (NYSE:ZYME – Get Rating) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 7,568,573 shares of the company’s stock, valued at approximately $59,489,000. Zymeworks comprises approximately 1.8% of EcoR1 Capital […]
Results presented today at ASCO 2023 and concurrently published in The Lancet Oncology demonstrate meaningful clinical benefit including antitumor activity, confirmed objective response rate
AMENDED AND RESTATED MANAGEMENT INFORMATION CIRCULAR FOR THE ANNUAL AND SPECIAL MEETING OF COMMON SHAREHOLDERS TO BE HELD ON JUNE 30, 2023 May 31,... | June 10, 2023